Whole-exome and transcriptome analyses of patients with ER-positive metastatic breast cancer identified mutations in ESR1, affecting its ligand-binding domain (LBD), suggesting that activating mutations in ESR1 is a key mechanism in acquired endocrine resistance in breast cancer therapy [48,49]. The gene discussed is ESR1; the disease is breast cancer.